CareLit · DOI-Nachweis · Pneumologie
DUAL study extension 2nd season: Benefit of Omalizumab and SIT over SIT alone maintained for GETE evaluation but not for symptom load
DOI 10.1055/s-2008-1074285
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Kopp, E Hamelmann, K Bergmann, U Wahn, C Sieder, S Stenglein, S Seyfried
ZeitschriftPneumologie
Ausgabe04/2008
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Previous study data generated in patients with grass- and rye pollen seasonal allergic asthma in 2006 have demonstrated a statistically significant and clinically relevant superiority of the combination of Xolair® (Omalizumab, OMA) plus a depigmented allergenic extract (Depigoid®) versus SIT monotherapy. There are now data available on the follow-up season in 2007 in which both arms have been treated wit…
Zitieren
Zitierempfehlung
M Kopp, E Hamelmann, K Bergmann, U Wahn, C Sieder, S Stenglein, S Seyfried (2008) DUAL study extension 2nd season: Benefit of Omalizumab and SIT over SIT alone maintained for GETE evaluation but not for symptom load. Pneumologie (04). https://doi.org/10.1055/s-2008-1074285
Mit CareLit weiterarbeiten